- Home
- DCBO vs EBS Comparison
DCBO vs EBS Comparison
Compare DCBO & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DCBO | EBS |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.5M | 663.3M |
| IPO Year | 2020 | 2006 |
Fundamental Metrics
Financial Performance| Metric | DCBO | EBS |
|---|---|---|
| Price | $22.01 | $13.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $35.50 | $15.00 |
| AVG Volume (30 Days) | 66.3K | ★ 829.8K |
| Earning Date | 02-27-2026 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.42 | N/A |
| EPS | 0.74 | ★ 1.35 |
| Revenue | $236,691,000.00 | ★ $788,900,000.00 |
| Revenue This Year | $13.67 | N/A |
| Revenue Next Year | $7.43 | $15.21 |
| P/E Ratio | $29.94 | ★ $9.89 |
| Revenue Growth | ★ 13.16 | N/A |
| 52 Week Low | $20.20 | $4.02 |
| 52 Week High | $43.94 | $14.06 |
Technical Indicators
Market Signals| Indicator | DCBO | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 61.06 |
| Support Level | $21.97 | $12.02 |
| Resistance Level | $23.45 | $14.06 |
| Average True Range (ATR) | 0.52 | 0.52 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 19.41 | 55.64 |
Price Performance
Historical ComparisonAbout DCBO Docebo Inc.
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.